Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Bipyramidal gold nanoparticles-assisted plasmonic photothermal therapy for ocular applications.
J Mater Chem B
January 2025
Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Department of Ophthalmology, Reina Sofia University Hospital and University of Cordoba, 14004 Cordoba, Spain.
Gold nanoparticles (AuNPs) play a key role in the field of nanomedicine due to their fascinating plasmonic properties as well as their great biocompatibility. An intriguing application is the use of plasmonic photothermal therapy (PPTT) mediated by anisotropic AuNPs irradiated with a near-infrared (NIR) laser for treating ocular diseases in ophthalmology. For this purpose, bipyramidal-shaped AuNPs (BipyAu), which were surface-functionalized with three different organic ligands (citrate, polystyrene sulphonate (PSS), and cetyltrimethylammonium bromide (CTAB)), were synthesized.
View Article and Find Full Text PDFComparative study of polymeric nanoparticles and traditional agents in dental implant decontamination.
J Appl Biomater Funct Mater
January 2025
Faculty of Dentistry, Department of Periodontics, Complutense University of Madrid, Madrid, Spain.
Peri-implant diseases, such as peri-implantitis, affect up to 47% of dental implant recipients, primarily due to biofilm formation. Current decontamination methods vary in efficacy, prompting interest in polymeric nanoparticles (NPs) for their antimicrobial and protein-specific cleaning properties. This study evaluated the efficacy of polymeric nanoparticles (NPs) in decontaminating titanium dental implants by removing proteinaceous pellicle layers and resisting recontamination.
View Article and Find Full Text PDFImpact of Imaging and Pharmacological Treatment Strategies in Refractory Ventricular Tachycardia in Critically Ill Patients: A Systematic Review.
Cureus
December 2024
Medicine, Universidad Santiago de Cali, Cali, COL.
Ventricular tachycardia (VT) is a life-threatening arrhythmia often leading to sudden cardiac death, particularly in critically ill patients. Refractory VT, characterized by recurrent episodes requiring intervention, poses unique challenges for management, necessitating advanced diagnostic and therapeutic strategies. This systematic review evaluates the impact of imaging and pharmacological treatments in managing refractory VT in critically ill patients.
View Article and Find Full Text PDFLong-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibition.
Front Oncol
January 2025
Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany.
Background: Dedifferentiated liposarcoma (DDLPS) is a rare mesenchymal cancer originating from the adipose tissue, with poor survival rates for most patients, highlighting the critical need for novel treatment options.
Case Description: This report examines the efficacy and safety of sequential pre-treatment with the marine-derived alkaloid trabectedin followed by checkpoint inhibition using the anti-PD-1 antibody nivolumab in a 63-year-old male patient with unresectable retroperitoneal DDLPS. Treatment was initiated at the time of the seventh relapse as part of the NitraSarc phase 2 multicenter trial for inoperable soft tissue sarcoma conducted by the German Interdisciplinary Sarcoma Group (GISG-15, ).
Treatment of neovascular age-related macular degeneration: one year real-life results with intravitreal Brolucizumab.
Front Med (Lausanne)
January 2025
Eye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences University of Campania "Luigi Vanvitelli", Naples, Italy.
Background: Age-related macular degeneration (AMD) is a prevalent cause of irreversible vision loss worldwide, particularly among the elderly population. Two forms of late AMD are described: neovascular AMD (nAMD), characterized by abnormal choroidal blood vessel growth, and atrophic (dry) AMD, involving retinal cell degeneration. Intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents have transformed nAMD treatment, with Brolucizumab emerging as a promising therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!